The Pre-Clinical process of the medical device, which enables the treatment of upper and lower respiratory tract infections with the indirect plasma process and the endoscope method, has been completed. Studies were done in cooperation with Ankara University Faculty of Pharmacy and Accredited Antimicrobial Laboratory.
Test bacteria used within the scope of Microbiology tests carried out at Ankara University/Faculty of Pharmacy were selected from bacteria in the American Type Culture Collection (ATCC) and used as standard in research and development activities. These; S. aureus (ATCC 25923), P. aeruginosa (ATCC 27853) and K. pneumoniae (ATCC 13383) bacteria. In the tests performed, an average of 80% bactericidal (bactericidal) effect was observed for all three bacterial species.
In accredited tests in the Anti-Microbe laboratory;
Plasma application was applied to surfaces contaminated with S. aureus (ATCC 6538) bacteria, and 87.7% bactericidal (bactericidal) effect was observed when applied for 2 minutes.
Plasma application was applied to surfaces contaminated with E.coli (ATCC 10356) bacteria and 61.16% bactericidal (bactericidal) effect was observed when applied for 2 minutes.
COVID-19 Conclusion: When the plasma device was applied to metal disc surfaces contaminated with COVID-19 (SARS-CoV-2) (Clinical Isolate) virus for 120 seconds, it showed a virucidal (virus killing) effect at the level of 51%.